APA Alıntı

Pellegatta, S., Eoli, M., Cuccarini, V., Anghileri, E., Pollo, B., Pessina, S., . . . Finocchiaro, G. (2018). Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide. Oncoimmunology.

Chicago Stili Alıntı

Pellegatta, Serena, et al. "Survival Gain in Glioblastoma Patients Treated With Dendritic Cell Immunotherapy Is Associated With Increased NK but Not CD8(+) T Cell Activation in the Presence of Adjuvant Temozolomide." Oncoimmunology 2018.

MLA Alıntı

Pellegatta, Serena, et al. "Survival Gain in Glioblastoma Patients Treated With Dendritic Cell Immunotherapy Is Associated With Increased NK but Not CD8(+) T Cell Activation in the Presence of Adjuvant Temozolomide." Oncoimmunology 2018.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..